4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2023)
4D Molecular Therapeutics (FDMT) reported Other financing activities of $260000.0 for Q2 2023, up 128.07% year-over-year from $114000.0 in Q2 2022, and up 276.81% quarter-over-quarter from $69000.0 in Q1 2023.
4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2023) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 4 years of Other financing activities data on file, last reported at $260000.0 in Q2 2023.
- Other financing activities for Q2 2023 came in at $260000.0, up 128.07% year-over-year; the trailing twelve-month figure through Jun 2024 was $329000.0 (down 24.71% YoY), and the FY2022 annual result was $468000.0, changed N/A from the prior year.
- Other financing activities rose to $260000.0 in Q2 2023 per FDMT's latest filing, from $69000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $946000.0 in Q1 2021 and troughed at -$946000.0 in Q4 2021.
- A 4-year average of $74272.7 and a median of $114000.0 in 2022 frame the typical range for Other financing activities.
- On a YoY basis, Other financing activities climbed as much as 149.47% in 2022 and fell as far as 74.0% in 2022.
- A 4-year view of Other financing activities shows it stood at -$348000.0 in 2020, then slumped by 171.84% to -$946000.0 in 2021, then surged by 149.47% to $468000.0 in 2022, then plunged by 44.44% to $260000.0 in 2023.
- Business Quant data shows FDMT's Other financing activities at $260000.0 in Q2 2023, $69000.0 in Q1 2023, and $468000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,000.00 |
| Jun 30, 2023 | 260,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 468,000.00 |
| Dec 31, 2022 | 468,000.00 |
| Sep 30, 2022 | -360,000.00 |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 114,000.00 |
| Jun 30, 2022 | 114,000.00 |
| Mar 31, 2022 | 246,000.00 |
| Mar 31, 2022 | 246,000.00 |
| Dec 31, 2021 | -946,000.00 |
| Dec 31, 2021 | -946,000.00 |
| Mar 31, 2021 | 946,000.00 |
| Mar 31, 2021 | 946,000.00 |
| Sep 30, 2020 | -348,000.00 |
| Sep 30, 2020 | -348,000.00 |
| Jun 30, 2020 | -26,000.00 |
| Jun 30, 2020 | -26,000.00 |